Key regulators of apoptosis execution as biomarker candidates in melanoma.
Resistance to apoptosis is frequently detected in malignant melanoma, a skin cancer with rapidly growing incidence rates. Apoptosis resistance may develop with disease progression and may be associated with the poor responsiveness of metastatic melanoma to apoptosis-inducing treatments, such as genotoxic chemotherapy and radiotherapy. Likewise, the efficacy of novel treatment options (targeted kinase inhibitors and immunotherapeutics) that indirectly lead to cell death may depend on the susceptibility of melanoma to apoptosis. At its core, apoptosis execution is regulated by the interplay between a comparatively small number of pro- and anti-apoptotic proteins, and consequently numerous studies have investigated the potential of these players as biomarker candidates. Here, we provide a comprehensive overview of biomarker discovery studies focusing on key regulators of apoptosis execution, critically review the findings of these studies, and outline strategies that address current limitations and challenges in exploiting regulators of apoptosis execution as prognostic or predictive biomarkers in melanoma.
Department of Physiology & Medical Physics; Royal College of Physics; Royal College of Surgeons in Ireland; Dublin 2, Ireland; Centre for Systems Medicine; Royal College of Surgeons in Ireland; Dublin 2, Ireland.
Emilie M
EM
Charles
Department of Physiology & Medical Physics; Royal College of Physics; Royal College of Surgeons in Ireland; Dublin 2, Ireland; Centre for Systems Medicine; Royal College of Surgeons in Ireland; Dublin 2, Ireland.
Markus
M
Rehm
APAF-1; IAP antagonist; XIAP; apoptosis; biomarker; caspases; melanoma